Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-25T08:58:43.618Z Has data issue: false hasContentIssue false
  • English
  • Français

Drug-induced psychosis in Parkinson's disease (I): manifestations and therapy

Published online by Cambridge University Press:  18 September 2015

E.CH. Wolters ,
G. Tissingh ,
M.A. Kuiper ,
W.A. Zwaan  and
M.W.I.M. Horstink
E.CH. Wolters*
Affiliation:
Afdeling Neurologie, Academisch Ziekenhuis der Vrije Universiteit
G. Tissingh
Affiliation:
Afdeling Neurologie, Academisch Ziekenhuis der Vrije Universiteit
M.A. Kuiper
Affiliation:
Afdeling Neurologie, Academisch Ziekenhuis der Vrije Universiteit
W.A. Zwaan
Affiliation:
Afdeling Psychiatrie, Academisch Ziekenhuis der Vrije Universiteit
M.W.I.M. Horstink
Affiliation:
Afdeling neurologie, 3, Academisch Ziekenhuis Nijmegen
*
Postbus 7057, 1007 MB Amsterdam, Tel. 020-5482818
Get access Rights & Permissions [Opens in a new window]

Summary

In this first part of a review on drug-induced psychosis in Parkinson's disease, the etiology, the clinical features and the therapeutic strategies will be discussed. The drugs used in the therapy of Parkinson's disease may lead to non-motor complications, such as delirium or hallucinations. Especially anti-cholinergics, respectivily dopaminometics, play an important role. Lowering the dose or even discontinuing the medication is the main therapeutic measure. The use of an atypical antipsychotic drug (clozapine) may be indicated.

Keywords

Parkinson's diseaseorganic mental disordersanticholinergicsdopamineatypical neurolepticsziekte van Parkinsonorganische Psychosyndromenanticholinergicadopamineatypische neuroleptica
Type
Research Article
Information
Acta Neuropsychiatrica , Volume 6 , Issue 2 , June 1994 , pp. 29 - 33
Copyright
Copyright © Scandinavian College of Neuropsychopharmacology 1994

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Literatuur

1.Fairweather, DS. Delirium. In: Jacoby, R, Oppenheimer, C eds. Psychiatry in the Elderly. Oxford: Oxford Univ Press 1991:647–75.Google Scholar
2.Stephens, DA. Psychotoxic effects of benzhexol hydrochloride (Artane). Br J Psychiat 1976;113:213–8.CrossRefGoogle Scholar
3.Dravid, AR. Deficits of cholinergic enzymes and muscarinic receptors in the hippocampus and striatum of senescent rats: effect of chronic hydergine treatment. Arch int Pharmacodyn 1983;264:195–202.Google ScholarPubMed
4.McGeer, EG. Aging and neurotransmitter metabolism in the human brain. In: Katzman, R, Terry, RD, Bick, KL eds. Alzheimer's Disease: senile Dementia and related Disorders. New York: Raven Press 1978:427–40.Google Scholar
5.Mayeux, R, Stern, Y, Mulvey, K, Cote, L. Reappraisal of temporary levodopa withdrawal (drug holiday) in Parkinson's disease. New Engl J Med 1985;313:724–7.CrossRefGoogle ScholarPubMed
6.Friedman, JH. The management of levodopa psychoses. Clin Neuropharmacol 1991;14:283–95.CrossRefGoogle ScholarPubMed
7.Hurwitz, TA, Calne, DB, Waterman, K. Treatment of dopaminemimetic psychosis in Parkinson's disease with electroconvulsive therapy. Can J neurol Sci 1988;15:32–4.CrossRefGoogle Scholar
8.Oh, JJ, Rummans, TA, O'Connor, MK, Ahlskog, JE. Cognitive impairment after ECT in patients with Parkinson's disease and psychiatric illness. Am J Psychiat 1992;149:271.Google ScholarPubMed